These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 2447572

  • 1. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.
    Rademaker M, Thomas RH, Provost G, Beacham JA, Cooke ED, Kirby JD.
    Postgrad Med J; 1987 Aug; 63(742):617-20. PubMed ID: 2447572
    [Abstract] [Full Text] [Related]

  • 2. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD.
    BMJ; 1989 Mar 04; 298(6673):561-4. PubMed ID: 2467711
    [Abstract] [Full Text] [Related]

  • 3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.
    J Rheumatol; 1992 Sep 04; 19(9):1407-14. PubMed ID: 1279170
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA, Isenberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM, Machin SJ.
    Br J Rheumatol; 1988 Jun 04; 27(3):220-6. PubMed ID: 2454140
    [Abstract] [Full Text] [Related]

  • 6. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H, Halkier-Sørensen L, Bjerring P, Heickendorff L.
    Acta Derm Venereol; 1996 May 04; 76(3):236-8. PubMed ID: 8800308
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J, Kaltenecker A, Schricker KT, Krais T, Schönberger A, Gevatter M, Hornstein OP.
    Dtsch Med Wochenschr; 1984 Sep 21; 109(38):1433-8. PubMed ID: 6383760
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E, Virgilio S, Ghirardi R, Martinelli M.
    Minerva Med; 1992 Nov 21; 83(11):739-44. PubMed ID: 1281297
    [Abstract] [Full Text] [Related]

  • 12. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A.
    Cochrane Database Syst Rev; 2000 Nov 21; 1998(2):CD000953. PubMed ID: 10796395
    [Abstract] [Full Text] [Related]

  • 13. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R.
    Clin Rheumatol; 2002 Jun 21; 21(3):244-50. PubMed ID: 12111631
    [Abstract] [Full Text] [Related]

  • 14. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N, Rada G.
    Medwave; 2015 Mar 09; 15(2):e6082. PubMed ID: 25826330
    [Abstract] [Full Text] [Related]

  • 15. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S.
    Rheumatology (Oxford); 2006 Aug 09; 45(8):999-1004. PubMed ID: 16484290
    [Abstract] [Full Text] [Related]

  • 16. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained.
    Kingma K, Wollersheim H, Thien T.
    J Cardiovasc Pharmacol; 1995 Sep 09; 26(3):388-93. PubMed ID: 8583779
    [Abstract] [Full Text] [Related]

  • 17. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep 09; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS, Belch JJ, Madhok R, Cappell H, Herrick A, Jayson M, Thompson JM.
    Clin Exp Rheumatol; 1993 Sep 09; 11(1):35-40. PubMed ID: 8453795
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.